Novo’s Wegovy and Ozempic removed from US FDA shortage list, compounders on notice

Reuters was nearly an hour ahead of rivals when the U.S. FDA said a shortage of Novo Nordisk’s weight-loss and diabetes drugs, Wegovy and Ozempic, was resolved. The update sent shares of Hims & Hers Health, which sells compounded versions of Wegovy, down more than 22%.